ZOONO GROUP LIMITED DISCLOSUREInsider Transactions (Form 3/4/5)

Change of Director's Interest Notice x4

1 | P a g e Zoono Group Limited (ASX: ZNO) ASX ANNOUNCEMENT 25 September 2026 Change of Directors’ Interests Notices (x4) Zoono Group Limited (Company) (ASX: ZNO) advises that Non-Executive Director, Mr. Marc Braterman, sold 782,022 fully paid ordinary shares in the Company (Shares) on 24 September 2026 at $0.05 per Share by way of an off-market trade. The Shares were sold to fund a personal matter. Following the sale, Mr. Braterman retains his contractual right to acquire up to 5,000,000 Shares subject to attainment of their vesting conditions. The Board recognised that the market could misread a sale of Shares by a recently appointed director as a reflection of that director's view of the Company's prospects. To avoid any such misunderstanding, and to show their continued confidence in the Company, the Company's other three directors, Mr. Paul Hyslop, Mr. Don Clarke and Ms. Elissa Hansen, agreed to purchase all of the Shares sold. Each bought 260,674 Shares, being one third of the Shares sold. All transactions complied with the Company's Securities Trading Policy and were completed during an open trading window. An Appendix 3Y, Change of Director’s Interest Notice for each director accompanies this announcement. This announcement has been authorised and approved for release to ASX by the Board of Zoono Group Limited. For further information, please contact: Zoono Group Limited Paul Hyslop Paul Ravlich Group MD Group CFO M: +64 21 659 977 M: +64 21 075 9176 E: [email protected] E: [email protected] For personal use only 2 | P a g e About Zoono Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono’s mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection. Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the ‘zoono molecule’, a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould. Zoono’s products have received numerous regulatory approvals and the company’s technology claims are supported by indep